Kidney Cancer

Urologists can easily miss or disregard these important aspects of contracts, which could come back to haunt them.

Noteworthy minimally invasive surgery research from AUA 2018 also included topics such as robot-assisted versus open radical cystectomy as well as minimally invasive retroperitoneal lymph node dissection in men with testis cancer.

Active surveillance in selected patients with localized renal masses 4 cm to 7 cm and a patient-derived xenograft system for predicting response to targeted and immune therapies in patients with metastatic RCC were among other noteworthy kidney cancer studies presented at AUA 2018.

A new frailty assessment tool can aid in the prognosis of urologic cancer patients, its inventors say.

A recent large, population-based comparative analysis examined outcomes for patients treated with percutaneous ablation, partial nephrectomy, or radical nephrectomy.

CMS’ Quality and Resource Use Report can help you understand your practice’s costs, says Robert A. Dowling, MD.

“The high initial complete response rate and durability observed in the interim analysis is very promising and suggests that UGN-101 could be an effective and well-tolerated noninvasive treatment for patients with UTUC,” says researcher Seth Paul Lerner, MD.

An analysis of trends in the management of renal masses shows growing use of active surveillance, although some data suggest “a proportion of surveillance cases may have been due to lack of access to care instead of truly choosing active surveillance,” says study author Ketan K. Badani, MD.

The approval of immune checkpoint inhibitor combination therapy may be the most significant advance in a decade for the treatment of metastatic renal cell carcinoma, an expert says.

While they may have potential anti-tumor effects in other cancers, non-steroidal anti-inflammatory drugs do not appear to confer a survival benefit in metastatic renal cell carcinoma.

High levels of visceral fat were associated with a significantly increased risk of death in women with clear cell renal cell carcinoma, but not in men, results of a recent retrospective study show.

“The findings should serve as a call to action for urologic specialists who care for patients with cancer,” says Alexander Kutikov, MD.

An immunotherapy combination of nivolumab (Opdivo) and ipilimumab (Yervoy) extended overall survival compared with sunitinib (SUTENT) as first-line treatment of patients with advanced or metastatic renal cell carcinoma.

A recent study suggests experimental "texture analysis" of renal masses via computed tomography scan holds promise as a technique to allow more effective risk stratification.

In today’s digital world, having an active professional presence online has become a must.

A 46-year-old male underwent a left laparoscopic radical nephrectomy for a cT1b renal cell carcinoma. Intra-operatively, a rent in the descending mesocolon was made during bowel mobilization but was not closed. Subsequently, the patient presented to the emergency room 4 days later with complaints of sudden onset sharp abdominal pain and nausea. A non-contrast computed tomography scan was obtained. What is the diagnosis?

"In the end, it is up to the surgeons who wish to continue to perform these robotic procedure to demonstrate their cost-effectiveness," writes Badar M. Mian, MD.

An updated guideline on localized kidney cancer as well as a look at active surveillance as initial management for renal masses <2 cm were among the noteworthy kidney cancer studies at the AUA annual meeting in Boston.

This article discusses the current status and potential future developments in immunotherapy for genitourinary malignancies with insights from urologic oncology specialists Hyung L. Kim, MD, and Daniel P. Petrylak, MD.

This article highlights the key points of two urologic cancer guidelines (which provide evidence-based guidance) and two consensus statements (which provide consensus recommendations by a multidisciplinary panel of experts) that have been published in the past year.

Persistent clinical benefit was seen among a small group of patients with metastatic renal cell carcinoma who had to discontinue therapy with the PD-1 inhibitor nivolumab (Opdivo) because of immune-related adverse events, according to a study presented at the Genitourinary Cancers Symposium in Orlando, FL.

Administration of broad-spectrum antibiotics in patients with metastatic renal cell carcinoma (RCC) undergoing treatment with immune checkpoint inhibitors may have a negative effect on the efficacy of the immunotherapy drugs, according to the results of a recent retrospective analysis.

Other pipeline developments discussed in this article include the initiation of an intravesical bladder cancer study, a gel treatment for ED that has met its primary endpoint, a patent awarded for the first rechargeable implantable SNM along with some other advancements.

A recent study of patients with a new diagnosis of microhematuria finds that rates of bladder and kidney cancer as well as urolithiasis depend on how thoroughly the patients are evaluated.

Results from a recent prospective trial suggest that active surveillance may be suitable for some patients with advanced renal cell carcinoma.

Once-daily treatment with cabozantinib (CABOMETYX), an oral tyrosine kinase inhibitor, significantly improves overall survival as well as progression-free survival and objective responses rates compared with everolimus (Afinitor) in previously treated patients with advanced renal cell carcinoma, according to final results from the phase III METEOR trial.

Other products discussed in this roundup include a smart-mobile connected ultrasound device, treatments for RCC, and more.

FDA approval of second-line therapies could mean an “embarrassment of riches” in this field, according to one expert.

The procedure maximally preserves normal renal parenchyma and provides better surgical precision than standard partial nephrectomy, researchers report.

To guide you through the 2016 AUA annual meeting and help maximize your time, Urology Times’ editorial board has reviewed the program to identify the key trends and noteworthy research at this year’s meeting.